$MRNA had a textbook bullish analyst setup heading into today's Phase 3 data.
Last 30 days:
• 7 target-price raises, zero cuts
• 2 upgrades, zero downgrades
• FY2030 EPS revisions up $0.53 to $5.19
16 brokers in consensus, but 22 of 24 still rated Hold or worse — classic underweight positioning before a catalyst.
Now the revision cascade starts. Expect 3–4 weeks of upgrades as analysts scramble to reprice the Phase 3 beat and the 50/50 Merck deal structure most notes are ignoring.
This is how you get momentum after a binary event — sentiment lags data, and the Street moves in waves.
Last 30 days:
• 7 target-price raises, zero cuts
• 2 upgrades, zero downgrades
• FY2030 EPS revisions up $0.53 to $5.19
16 brokers in consensus, but 22 of 24 still rated Hold or worse — classic underweight positioning before a catalyst.
Now the revision cascade starts. Expect 3–4 weeks of upgrades as analysts scramble to reprice the Phase 3 beat and the 50/50 Merck deal structure most notes are ignoring.
This is how you get momentum after a binary event — sentiment lags data, and the Street moves in waves.